C

California Neuroscience Research Medical Group | Sherman Oaks, CA

Research site

(Unclaimed)

Location

4835 Van Nuys Boulevard 104, Sherman Oaks, California, United States of America

Site insights

Top conditions

Top treatments

Gantenerumab

Aducanumab

Rimegepant

LY3002813

Donanemab

OPC-34712

Troriluzole

BMS-708163

Rapastinel

PRX-03140

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 50 total trials

New

A Study of Brenipatide in Participants With Major Depressive Disorder (RENEW-MDD-3)

This study evaluates the safety and efficacy of brenipatide (LY3537031) as an add on therapy in participants with major depression who still have sym...

Not yet enrolling

Major Depressive Disorder

Drug: Brenipatide

Drug: Placebo

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting

Alzheimer's Disease

Mental Disorders

Drug: Placebo

Drug: Donanemab

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder

This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, s...

Enrolling

Generalized Anxiety Disorder

Drug: SEP-363856

Other: Placebo

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Active, not recruiting

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446